A cationic liposome–DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets

Liu, Feng; Sun, Xiangjie; Fairman, Jeff; Lewis, David B.; Katz, Jacqueline M.; Levine, Min Z.; Tumpey, Terrence M.; Lu, Xiuhua

doi:10.1016/j.virol.2016.02.024

Cited by 16 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome the problem of low immunogenicity of traditional inactivated vaccines, repeated vaccinations and increased antigen doses are often required [ 30 ], which do not allow for “dose-sparing” and will increase the chances of vaccine shortages. Adjuvants also need to be used to improve the immunogenicity of vaccines against avian IAV [ 31 ].…”

Section: Preparing For Future Pandemicsmentioning

confidence: 99%

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development

2018

View full text Add to dashboard Cite

Influenza A viruses can infect a wide range of hosts, creating opportunities for zoonotic transmission, i.e., transmission from animals to humans, and placing the human population at constant risk of potential pandemics. In the last hundred years, four influenza A virus pandemics have had a devastating effect, especially the 1918 influenza pandemic that took the lives of at least 40 million people. There is a constant risk that currently circulating avian influenza A viruses (e.g., H5N1, H7N9) will cause a new pandemic. Vaccines are the cornerstone in preparing for and combating potential pandemics. Despite exceptional advances in the design and development of (pre-)pandemic vaccines, there are still serious challenges to overcome, mainly caused by intrinsic characteristics of influenza A viruses: Rapid evolution and a broad host range combined with maintenance in animal reservoirs, making it near impossible to predict the nature and source of the next pandemic virus. Here, recent advances in the development of vaccination strategies to prepare against a pandemic virus coming from the avian reservoir will be discussed. Furthermore, remaining challenges will be addressed, setting the agenda for future research in the development of new vaccination strategies against potentially pandemic influenza A viruses.

show abstract

Section: Preparing For Future Pandemicsmentioning

confidence: 99%

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development

2018

View full text Add to dashboard Cite

show abstract

“…These diseases are required vaccine formulations that not only promote strong cellular or Th1based immune responses, but also induce humoral or Th2 immune responses and mucosal immune responses [6]. Therefore, to enhance the vaccines immune efficacy and achieve sustained release and mucosal immunity, several strategies was carried out: utilizing an efficient adjuvant, implementing an efficient delivery system, and using appropriate effective antigen presentation targets [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Applications of polymer-based nanoparticles in vaccine field

Guo

Utupova

et al. 2019

Nanotechnology Reviews

View full text Add to dashboard Cite

Polymer-based nanoparticles have good solubility, stability, safety, and sustained release,which increases the absorption of loaded drugs, protects the drugs from degradation, and prolongs their circulation time and targeted delivery. Generally, we believe that prevention and control of infectious diseases through inoculation is the most efficient measure. However, these vaccines including live attenuated vaccines, inactivated vaccines, protein subunit vaccines, recombinant subunit vaccines, synthetic peptide vaccines and DNA vaccines have several defects, such as immune tolerance, poor immunogenicity, low expression level and induction of respiration pathological changes. All kinds of biodegradable natural and synthetic polymers play major roles in the vaccine delivery system to control the release of antigens for an extended period of time. In addition, these polymers also serve as adjuvants to enhance the immunogenicity of vaccine. This review mainly introduces natural and synthetic polymer-based nanoparticles and their formulation and properties. Moreover, polymer-based nanoparticles as adjuvants and delivery carriers in the applications of vaccine are also discussed. This review provides the basis for further operation of nano vaccines by utilizing the polymer-based nanoparticles as vaccine adjuvants and delivery systems. Polymer-based nanoparticles have exhibited great potential in improving the immunogenicity of antigens and the development of nano vaccines in future.

show abstract

“…All of these shortages limit the wider application of DNA vaccines, especially in large animal models (Fowler et al., 2012 ). Therefore, effective strategies are selected to improve the efficacy of vaccines, such as the use of a powerful adjuvant to enhance immunogenicity, optimization of the delivery methods, selection of appropriate routes of immunization, and targeting for effective antigen presentation (Manoj & Babiuk, 2004 ; Xu et al., 2011 ; Di Giacomo et al., 2015 ; Liu et al., 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Quaternized chitosan nanoparticles loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis elicit immune response in chicken after intranasal administration

Zhao

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

Newcastle disease (ND) and infectious bronchitis (IB) are important diseases, which cause respiratory diseases in chickens, resulting in severely economic losses in the poultry industry. In this study, N-2-hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC) and N,O-carboxymethyl chitosan (CMC) were synthesized as adjuvant and delivery carrier for vaccine antigens. N-2-HACC-CMC/NDV/IBV nanoparticles (NPs) (NDV/La Sota and IBV/H120 encapsulated in N-2-HACC-CMC NPs) and N-2-HACC-CMC/NDV-IBV NPs (the mixing of N-2-HACC-CMC/NDV NPs and N-2-HACC-CMC/IBV NPs in a ratio of 1:1) were prepared by the polyelectrolyte composite method, respectively. Both nanoparticles exhibited lower cytotoxicity and higher stability. Their bioactivities were maintained when they were stored at 37 °C for three weeks. Release assay in vitro showed that both NDV and IBV could be sustainably released from the nanoparticles after an initial burst release. In vivo immunization of chickens showed that N-2-HACC-CMC/NDV/IBV NPs or N-2-HACC-CMC/NDV-IBV NPs intranasally induced higher titers of IgG and IgA antibodies, significantly promoted proliferation of lymphocytes and induced higher levels of interleukine-2 (IL-2), IL-4 and interferon-γ (IFN-γ) than the commercially combined attenuated live vaccine did. This is the first study in the field of animal vaccines demonstrating that intranasal administration of chickens with antigens (NDV and IBV) encapsulated with chitosan derivative could induce humoral, cellular, and mucosal immune responses, which protected chickens from the infection of highly virulent NDV and IBV. This study indicated that N-2-HACC-CMC could be used as an efficient adjuvant and delivery carrier for further development of mucosal vaccines and drugs and could have an immense application potential in medicine.

show abstract

A cationic liposome–DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets

Cited by 16 publications

References 48 publications

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development

Applications of polymer-based nanoparticles in vaccine field

Quaternized chitosan nanoparticles loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis elicit immune response in chicken after intranasal administration

Contact Info

Product

Resources

About